CSL Behring has joined the Pharmaceutical Research and Manufacturers of America (PhRMA) and Chief Executive Officer & Managing Director Paul Perreault is now serving on the organization’s board of directors.
PhRMA is a representative organization for the leading innovative biopharmaceutical research companies in the United States. The Washington-based group advocates for public policies that support innovative medical research and improve treatments for patients.
CSL Behring is joining PhRMA at a particularly critical time for collaboration among the science community. More than half of the group’s member companies, including CSL Behring, have launched programs aimed at detecting, preventing or treating coronavirus. Alongside fellow PhRMA member Takeda, CSL Behring co-founded the unprecedented CoVIg-19 Plasma Alliance last year, which is working on a potential hyperimmune treatment for COVID-19.
CSL Behring’s dedication to finding innovative treatments for those living with rare and serious conditions dovetails with PhRMA’s mission of discovering and developing medicines to enhance patients’ lives. PhRMA President and CEO Stephen Ubl cited that fact in announcing CSL Behring’s membership last month.
“Their resolute pursuit of new treatments and cures that can better the lives of patients will assist our association as we work with policymakers and stakeholders on common-sense policy solutions to improve the health care system,” Ubl said in a statement.
